|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0013216,
umls-concept:C0036043,
umls-concept:C0079419,
umls-concept:C0205195,
umls-concept:C0205225,
umls-concept:C0205314,
umls-concept:C0205460,
umls-concept:C0282641,
umls-concept:C0441655,
umls-concept:C0449445,
umls-concept:C0679622,
umls-concept:C1510800,
umls-concept:C1549781
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-8-30
|
|
pubmed:abstractText |
: Primary systemic therapy (PST) is the standard approach to the management of patients with locally advanced breast cancer (LABC). The authors hypothesized that the intratumoral administration of a nonreplicating adenoviral vector (Ad5) that contains the human wild-type p53, AdCMV-p53, combined with chemotherapy, could increase the efficacy of PST as measured by pathologic complete response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
107
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
935-44
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:16874816-Adenoviruses, Human,
pubmed-meshheading:16874816-Adult,
pubmed-meshheading:16874816-Aged,
pubmed-meshheading:16874816-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16874816-Breast Neoplasms,
pubmed-meshheading:16874816-Combined Modality Therapy,
pubmed-meshheading:16874816-Doxorubicin,
pubmed-meshheading:16874816-Female,
pubmed-meshheading:16874816-Gene Therapy,
pubmed-meshheading:16874816-Gene Transfer Techniques,
pubmed-meshheading:16874816-Genes, p53,
pubmed-meshheading:16874816-Genetic Vectors,
pubmed-meshheading:16874816-Humans,
pubmed-meshheading:16874816-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:16874816-Middle Aged,
pubmed-meshheading:16874816-Survival Rate,
pubmed-meshheading:16874816-Taxoids,
pubmed-meshheading:16874816-Transgenes
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach.
|
|
pubmed:affiliation |
Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77230, USA. mcristof@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
